Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer

被引:70
作者
Lowe, Kimberly A. [1 ]
Shah, Chirag [2 ]
Wallace, Erin [1 ]
Anderson, Garnet [1 ]
Paley, Pamela
McIntosh, Martin [1 ]
Andersen, M. Robyn [1 ]
Scholler, Nathalie [3 ]
Bergan, Lindsay [1 ]
Thorpe, Jason [1 ]
Urban, Nicole [1 ]
Drescher, Charles W. [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1158/1055-9965.EPI-08-0150
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective: To evaluate if serum levels of candidate ovarian cancer biomarkers vary with individual characteristics of healthy women who are likely candidates for an ovarian cancer screening program. Methods: We analyzed serum CA125, mesothelin, and HE4 levels in a sample of 1.55 healthy postmenopausal women at increased risk for developing ovarian cancer based on personal and family cancer history. Information on reproductive, family and medical histories, lifestyle factors, and anthropometry was collected by self-report. Twenty-two factors were examined using univariate and multiple linear regression models for the three biomarker levels. Results: In the multivariate models, CA125 levels were significantly higher in women who had used talcum powder (P = 0.02) and were lower in women who were parous (P = 0.05). Mesothelin levels were significantly higher in older women (P = 0.01) and lower in heavier women (P = 0.03). HE4 levels were higher in older women (P = 0.001) and in women who began menstruating at an older age (P = 0.03). Conclusions: CA125, mesothelin, and HE4 levels in healthy, postmenopausal women at increased risk for ovarian cancer are significantly associated with a few ovarian cancer risk factors. Since the effects of these personal characteristics on these serum markers are not large, their incorporation in screening algorithms may be unnecessary. This is true especially if a longitudinal algorithm is used because the marker level at the previous screen reflects personal characteristics such as age, body mass index, and age of menarche. Understanding the influence of personal factors on levels of novel early detection markers in healthy, unaffected women may have clinical utility in interpreting biomarker levels.
引用
收藏
页码:2480 / 2487
页数:8
相关论文
共 30 条
[1]
AFIFI A, 2004, APPL REGRESSION ANAL
[2]
AFIFI A, 2004, VARIABLE SELECTION R
[3]
New tumor markers: CA125 and beyond [J].
Bast, RC ;
Badgwell, D ;
Lu, Z ;
Marquez, R ;
Rosen, D ;
Liu, J ;
Baggerly, KA ;
Atkinson, EN ;
Skates, S ;
Lokshin, A ;
Menon, U ;
Jacobs, I ;
Lu, K .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 :274-281
[4]
CA 125: The past and the future [J].
Bast, RC ;
Xu, FJ ;
Yu, YH ;
Barnhill, S ;
Zhang, Z ;
Mills, GB .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (04) :179-187
[5]
Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/mesothelin-dependent cell attachment [J].
Bergan, Lindsay ;
Gross, Jennifer A. ;
Nevin, Barry ;
Urban, Nicole ;
Scholler, Nathalie .
CANCER LETTERS, 2007, 255 (02) :263-274
[6]
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: Findings from the initial screen of a randomized trial [J].
Buys, SS ;
Partridge, E ;
Greene, MH ;
Prorok, PC ;
Reding, D ;
Riley, TL ;
Hartge, P ;
Fagerstrom, RM ;
Chia, D ;
Izmirlian, G ;
Fouad, M ;
Ragard, LR ;
Johnson, CC ;
Gohagan, JK .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (05) :1630-1639
[7]
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas [J].
Drapkin, R ;
von Horsten, HH ;
Lin, YF ;
Mok, SC ;
Crum, CP ;
Welch, WR ;
Hecht, JL .
CANCER RESEARCH, 2005, 65 (06) :2162-2169
[8]
Hellström I, 2003, CANCER RES, V63, P3695
[9]
Mesothelin variant 1 is released from tumor cells as a diagnostic marker [J].
Hellstrom, Ingegerd ;
Raycraft, John ;
Kanan, Sandra ;
Sardesai, Niranjan Y. ;
Verch, Thorsten ;
Yang, Yi ;
Hellstrom, Karl Erik .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (05) :1014-1020
[10]
Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO